World's Best Scientists 2026 revealed!
Karel Pavelka

Karel Pavelka

Award Badge
Medicine
Czechia
2023

D-Index & Metrics

Medicine

D-Index
86
Citations
55373
World Ranking
13839
National Ranking
7

Karel Pavelka publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Karel Pavelka sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 610 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 656 publications — 77th percentile

77% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Karel Pavelka D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Karel Pavelka sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 399 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 86 D-Index — 31st percentile

31% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Research.com Recognitions

  • 2023 - Research.com Medicine in Czechia Leader Award
  • 2022 - Research.com Medicine in Czechia Leader Award

Overview

Karel Pavelka is affiliated with Charles University in the Czech Republic. Their research predominantly falls within the field of Medicine, with a focus on Rheumatology as well as Immunology, Pathology and Forensic Medicine, Epidemiology, and Psychiatry and Mental Health as subfields of study.

Their scholarly output includes significant engagement with topics such as Rheumatoid Arthritis Research and Therapies, Spondyloarthritis Studies and Treatments, Psoriasis: Treatment and Pathogenesis, Systemic Sclerosis and Related Diseases, Systemic Lupus Erythematosus Research, Fibromyalgia and Chronic Fatigue Syndrome Research, and Inflammatory Myopathies and Dermatomyositis.

Frequent coauthors contributing to the body of work alongside Pavelka include Ladislav Šenolt, Jiří Vencovský, Jakub Závada, Michal Tomčík, and Žiga Rotar, each reflecting collaborations across multiple projects.

They have published in several notable scientific venues, with repeated contributions to:

  • Annals of the Rheumatic Diseases
  • Lara D. Veeken
  • Scientific Reports
  • RMD Open
  • Arthritis Research & Therapy

Selected recent papers illustrate the scope and application of Pavelka's research:

  • "Plasma Hsp90 levels in patients with systemic sclerosis and relation to lung and skin involvement: a cross-sectional and longitudinal study" (2021, Scientific Reports)
  • "EULAR recommendations for the non-pharmacological core management of hip and knee osteoarthritis: 2023 update" (2024, Annals of the Rheumatic Diseases)
  • "Effectiveness of TNF-inhibitors, abatacept, IL6-inhibitors and JAK-inhibitors in 31 846 patients with rheumatoid arthritis in 19 registers from the 'JAK-pot' collaboration" (2022, Annals of the Rheumatic Diseases)
  • "The impact of seropositivity on the effectiveness of biologic anti-rheumatic agents: results from a collaboration of 16 registries" (2020, Lara D. Veeken)
  • "Drug retention, inactive disease and response rates in 1860 patients with axial spondyloarthritis initiating secukinumab treatment: routine care data from 13 registries in the EuroSpA collaboration" (2020, RMD Open)

Best Publications

  • EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update

    Josef S Smolen;Robert Landewé;Ferdinand C Breedveld;Maya Buch;Maya Buch

  • Plasma Hsp90 levels in patients with systemic sclerosis and relation to lung and skin involvement: a cross-sectional and longitudinal study.

    Hana Štorkánová;Sabína Oreská;Maja Špiritović;Barbora Heřmánková

  • Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial

    Lars Klareskog;Désirée van der Heijde;Julien P de Jager;Andrew Gough

  • The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment

    Ferdinand C Breedveld;Michael H Weisman;Arthur F Kavanaugh;Stanley B Cohen

  • EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs

    Josef S. Smolen;Robert Landewé;Ferdinand C Breedveld;Maxime Dougados

  • EULAR Recommendations 2003: an evidence based approach to the management of knee osteoarthritis: Report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT)

    K M Jordan;N K Arden;M Doherty;B Bannwarth

  • EULAR recommendations for the non-pharmacological core management of hip and knee osteoarthritis

    Linda Fernandes;Kåre B Hagen;Johannes W J Bijlsma;Oyvor Andreassen

  • 2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis

    J Braun;R van den Berg;X Baraliakos;H Boehm

  • Treatment of rheumatoid arthritis with recombinant human interleukin‐1 receptor antagonist

    Barry Bresnihan;José Maria Alvaro‐Gracia;Mark Cobby;Michael Doherty

  • EULAR evidence based recommendations for the management of hip osteoarthritis: report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT)

    W. Zhang;M. Doherty;B. F. Leeb;L. Alekseeva

  • Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate.

    R N Maini;P C Taylor;J Szechinski;K Pavelka

  • European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update.

    L Gossec;J S Smolen;S Ramiro;M de Wit

  • ASAS/EULAR recommendations for the management of ankylosing spondylitis

    J. Zochling;D. Van Der Heijde;R. Burgos-Vargas;E. Collantes

  • Glucosamine sulfate use and delay of progression of knee osteoarthritis: a 3-year, randomized, placebo-controlled, double-blind study.

    Karel Pavelka;Jindriska Gatterova;Marta Olejarova;Stanislav Machacek

  • EULAR evidence-based recommendations for the diagnosis of knee osteoarthritis

    W Zhang;M Doherty;G Peat;S Ma Bierma-Zeinstra

  • Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial

    Cem Gabay;Paul Emery;Ronald van Vollenhoven;Ara Dikranian

  • Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.

    Edward Keystone;Désireé Van Der Heijde;David Mason;Robert Landewé

  • EULAR recommendations for the management of knee osteoarthritis: report of a task force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT)

    A Pendleton;N Arden;M Dougados;M Doherty

  • FRI0298 The Impact of DMARD Co-Therapy on Abatacept Effectiveness in Rheumatoid Arthritis Patients. A Pan-European Analysis of RA Registries

    A. Finckh;D. Neto;J. Gomez-Reino;F. Iannone

  • EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs

    J. S. Smolen;R. Landewé;F. C. Breedveld;M. Dougados

Frequent Co-Authors

Cem Gabay
Cem Gabay University of Geneva
Tore K. Kvien
Tore K. Kvien University of Oslo
Paul Emery
Paul Emery University of Leeds
Olivier Bruyère
Olivier Bruyère University of Liège
Maxime Dougados
Maxime Dougados Hôpital Cochin
Jean-Yves Reginster
Jean-Yves Reginster University of Liège
Xavier Mariette
Xavier Mariette University of Paris-Saclay
Michael T. Nurmohamed
Michael T. Nurmohamed University of Amsterdam
Ronald F. van Vollenhoven
Ronald F. van Vollenhoven University of Amsterdam
Josef S. Smolen
Josef S. Smolen Medical University of Vienna

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For those interested in healthcare careers beyond traditional medical school, numerous online degree options exist. Popular career pathways include nursing, healthcare administration, and advanced practice roles. Online programs offer the flexibility to balance study with work or family commitments.

Nurses looking to specialize in mental health can explore msn to pmhnp online programs, which provide a fast-track to becoming a Psychiatric Mental Health Nurse Practitioner. For those interested in the business and leadership side of healthcare, a healthcare administration degree cost breakdown helps identify programs that fit your budget.

Graduate degrees are also accessible online. If you’re seeking advanced management roles, consider an affordable mha online program. Aspiring to the highest nursing qualifications? The best online dnp programs prepare nurses for leadership, research, and clinical practice at the doctoral level.

Exploring these online degrees opens numerous pathways in medicine and healthcare, catering to diverse interests and career goals.

Best Scientists Citing Karel Pavelka

Trending Scientists

Recently Published Articles